GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Linda Gigliotti, MS, RDN, CDCES, FAND, about combining the use of GLP-1 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

This breakthrough confirms a completely novel allosteric activation mechanism for the GLP-1 receptor ... new chemotype with an entirely unique binding mode. Biolexis is actively completing ...

Glucagon-like peptide 1 (GLP-1) receptor agonists are transforming the treatment landscape for type 2 diabetes ( T2D) and obesity, in addition to their cardiovascular benefits. These drugs also ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially developed ... (DHEAS), while simultaneously increasing sex hormone binding globulin (SHBG) levels. These shifts help to restore ...

What are the most concerning side effects of Ozempic and other weight-loss drugs? - Gastrointestinal and cardiovascular ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

CryoEM Confirms a First-in-Class Allosteric Binding Mode, Validating MolecuLernTM ... its first-in-class oral small-molecule GLP-1 receptor agonist. This breakthrough confirms a completely novel ...

More Type 1 Diabetics Are Obese, Taking GLP-1 Drugs By Dennis Thompson HealthDay Reporter MONDAY, March 31, 2025 (HealthDay News) -- Use of cutting-edge weight-loss drugs like Ozempic and Zepbound ...